# Metabolic Parkinson’s disease

## TL;DR

Parkinson’s disease is linked to metabolic disorders like diabetes and obesity, suggesting shared mechanisms and potential cross-treatment benefits.

## Contribution

The paper highlights a novel perspective on Parkinson’s disease by connecting it to metabolic dysfunctions and exploring shared therapeutic interventions.

## Key findings

- Metabolic disorders and Parkinson’s disease share cellular damage mechanisms like mitochondrial dysfunction and oxidative stress.
- Antidiabetic drugs like metformin show neuroprotective effects in Parkinson’s disease.
- Antiparkinsonian drugs like bromocriptine also improve glycemic control in diabetes, suggesting a cross-efficacy.

## Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder primarily characterized by the loss of dopaminergic neurons in the substantia nigra. While most cases are sporadic, there is growing evidence of a link between PD and metabolic dysfunctions such as type 2 diabetes mellitus, obesity, and metabolic syndrome. Proposed pathogenic mechanisms underlying this overlap include insulin resistance and chronic inflammation. Similar patterns of cellular damage are observed in both metabolic disorders and PD, including mitochondrial dysfunction, impaired autophagy, oxidative stress, endoplasmic reticulum stress, and gut microbiota alterations. Given the current lack of disease-modifying therapies for PD, there is increasing interest in interventions traditionally used to treat metabolic conditions, such as lifestyle and dietary modifications. Notably, antidiabetic drugs like metformin and incretin mimetics have shown beneficial effects in PD due to their neuroprotective and anti-inflammatory properties, their ability to restore insulin sensitivity, and their role in reducing neuronal susceptibility to toxic insults, as demonstrated in both preclinical and clinical studies. Conversely, traditionally antiparkinsonian drugs such as bromocriptine have long been approved for improving glycemic control in diabetes. This cross-efficacy between drugs used for the two conditions may indirectly support the hypothesis of a shared pathogenesis. A deeper understanding of the connections between metabolic disorders and PD could pave the way for novel preventive and therapeutic strategies.